ADCT-212 - ADC Therapeutics
mipasetamab uzoptirine (ADCT-601) - Overland ADCT BioPharma
camidanlumab tesirine (ADCT-301) - Genmab, ADC Therapeutics
ADCT-701 - ADC Therapeutics
Zynlonta (loncastuximab tesirine) - Overland ADCT BioPharma, Mitsubishi Tanabe
https://www.businesswire.com/news/home/20220303005259/en/ADC-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Provides-Business-Updates
 
Mar 3, 2022
 
Prev Next